NextCure reports $41.8M cash; SIM0505 data Q2 2026, LNCB74 delayed to H2 2026

NextCure, Inc.

Preliminary cash, cash equivalents and marketable securities of $41.8M as of Dec 31, 2025; runway into H1 2027.
SIM0505 (CDH6 ADC) Phase 1 dose escalation data expected Q2 2026; dose optimization starts H1 2026.
LNCB74 (B7-H4 ADC) higher dose cohorts underway; proof-of-concept data delayed from H1 to H2 2026.
Both programs target gynecological cancers; LNCB74 now includes adenoid cystic carcinoma.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.